Guggenheim Capital LLC lowered its holdings in shares of Ellsworth Growth and Income Fund Ltd. (NYSEAMERICAN:ECF – Get Rating) by 18.5% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 107,290 shares of the investment management company’s stock after selling 24,364 shares during the period. Guggenheim Capital LLC owned about 0.77% of Ellsworth Growth and Income Fund worth $860,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Captrust Financial Advisors bought a new stake in Ellsworth Growth and Income Fund during the 2nd quarter worth $105,000. Private Advisor Group LLC bought a new stake in Ellsworth Growth and Income Fund during the 3rd quarter worth $169,000. Quantedge Capital Pte Ltd bought a new stake in Ellsworth Growth and Income Fund during the 1st quarter worth $178,000. Atria Wealth Solutions Inc. bought a new stake in Ellsworth Growth and Income Fund during the 1st quarter worth $200,000. Finally, Cambridge Investment Research Advisors Inc. grew its position in shares of Ellsworth Growth and Income Fund by 7.1% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 26,290 shares of the investment management company’s stock valued at $211,000 after buying an additional 1,737 shares during the last quarter. Institutional investors and hedge funds own 28.24% of the company’s stock.
Ellsworth Growth and Income Fund Price Performance
NYSEAMERICAN ECF opened at $8.66 on Wednesday. Ellsworth Growth and Income Fund Ltd. has a 12 month low of $7.90 and a 12 month high of $10.78.
Ellsworth Growth and Income Fund Announces Dividend
About Ellsworth Growth and Income Fund
Operates as a closed-end, diversified management company and invests primarily in convertible securities. It invests in stocks of companies across market capitalizations.
Featured Articles
- Get a free copy of the StockNews.com research report on Ellsworth Growth and Income Fund (ECF)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Ellsworth Growth and Income Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ellsworth Growth and Income Fund and related companies with MarketBeat.com's FREE daily email newsletter.